Vimarsana
Biggest News Aggregation in the World

Both Glycoconnect News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Both Glycoconnect. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Both Glycoconnect Today - Breaking & Trending Today

Another Award for Synaffix: 'Business Development Team of Year' at the Scrip Awards - Vimarsana News

Another Award for Synaffix: 'Business Development Team of Year' at the Scrip Awards

/PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of...

Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering - Vimarsana News

Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering

/PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of...

Synaffix Inks Deal with MacroGenics to Enable Next Generation ADCs - Vimarsana News

Synaffix Inks Deal with MacroGenics to Enable Next Generation ADCs

/PRNewswire/ -- Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug...

Synaffix Announces Expansion of Mersana License Deal to a Total Potential Value Exceeding $1 Billion - Vimarsana News

Synaffix Announces Expansion of Mersana License Deal to a Total Potential Value Exceeding $1 Billion

/PRNewswire/ -- Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug...

Synaffix Announces Expansion of Mersana License Deal to a Total Potential Value Exceeding $1 Billion - Vimarsana News

Synaffix Announces Expansion of Mersana License Deal to a Total Potential Value Exceeding $1 Billion

/PRNewswire/ -- Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug...